期刊
CANCER IMMUNOLOGY RESEARCH
卷 2, 期 5, 页码 487-500出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-13-0217
关键词
-
资金
- BIIR
- Baylor University Medical Center Foundation
- Cancer Prevention Research Institute of Texas
- NIH/NCI
Our studies showed that tumor-infiltrating dendritic cells (DC) in breast cancer drive inflammatory Th2 (iTh2) cells and protumor inflammation. Here, we show that intratumoral delivery of the beta-glucan curdlan, a ligand of dectin-1, blocks the generation of iTh2 cells and prevents breast cancer progression in vivo. Curdlan reprograms tumor-infiltrating DCs via the ligation of dectin-1, enabling the DCs to become resistant to cancer-derived thymic stromal lymphopoietin (TSLP), to produce IL-12p70, and to favor the generation of Th1 cells. DCs activated via dectin-1, but not those activated with TLR-7/8 ligand or poly I:C, induce CD8(+) T cells to express CD103 (alpha E integrin), a ligand for cancer cells, E-cadherin. Generation of these mucosal CD8(+) T cells is regulated by DC-derived integrin alpha vb8 and TGF-beta activation in a dectin-1-dependent fashion. These CD103(+)CD8(+) mucosal T cells accumulate in the tumors, thereby increasing cancer necrosis and inhibiting cancer progression in vivo in a humanized mouse model of breast cancer. Importantly, CD103(+)CD8(+) mucosal T cells elicited by reprogrammed DCs can reject established cancer. Thus, reprogramming tumor-infiltrating DCs represents a new strategy for cancer rejection. (C) 2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据